MX2022013455A - Tgfî²r2 extracellular domain truncated molecule, fusion protein of tgfî²r2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein. - Google Patents
Tgfî²r2 extracellular domain truncated molecule, fusion protein of tgfî²r2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein.Info
- Publication number
- MX2022013455A MX2022013455A MX2022013455A MX2022013455A MX2022013455A MX 2022013455 A MX2022013455 A MX 2022013455A MX 2022013455 A MX2022013455 A MX 2022013455A MX 2022013455 A MX2022013455 A MX 2022013455A MX 2022013455 A MX2022013455 A MX 2022013455A
- Authority
- MX
- Mexico
- Prior art keywords
- tgfî2r2
- fusion protein
- extracellular domain
- domain truncated
- truncated molecule
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Provided are multiple types of TGFβR2 in truncated forms and a fusion protein constructed by TGFβR2 and EGFR antibody HPA8; also provided are a nucleic acid (comprising heavy/light chain variable regions) encoding the antibody, and a vector, a pharmaceutical composition, and a kit comprising the nucleic acid; further provided is a fusion protein of the prepared truncated form of TGFβR2 receptor protein and a targeted EGFR and other multiple types of tumor target antibodies.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010351280 | 2020-04-28 | ||
PCT/CN2021/089782 WO2021218883A1 (en) | 2020-04-28 | 2021-04-26 | TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013455A true MX2022013455A (en) | 2022-11-16 |
Family
ID=78331770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013455A MX2022013455A (en) | 2020-04-28 | 2021-04-26 | Tgfî²r2 extracellular domain truncated molecule, fusion protein of tgfî²r2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230257469A1 (en) |
EP (1) | EP4144764A4 (en) |
JP (1) | JP2023523981A (en) |
KR (1) | KR20230003114A (en) |
CN (1) | CN115335411A (en) |
AU (1) | AU2021264846A1 (en) |
BR (1) | BR112022021785A2 (en) |
CA (1) | CA3176671A1 (en) |
MX (1) | MX2022013455A (en) |
WO (1) | WO2021218883A1 (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK2542590T4 (en) * | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | COMPOSITIONS AND PROCEDURE FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS |
RU2662991C2 (en) * | 2013-03-12 | 2018-07-31 | Биокон Лтд. | Fusion immunomodulatory proteins and methods for making same |
JP2016528295A (en) * | 2013-08-22 | 2016-09-15 | アクセルロン ファーマ, インコーポレイテッド | TGF-beta receptor type II mutant and use thereof |
AU2015231001A1 (en) * | 2014-03-21 | 2016-09-29 | Abbvie Inc. | Anti-EGFR antibodies and antibody drug conjugates |
PL3628049T3 (en) * | 2017-05-04 | 2023-09-25 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
UA128306C2 (en) * | 2017-05-12 | 2024-06-05 | Джянгсу Хенгруй Медісін Ко., Лтд. | FUSION PROTEIN CONTAINING TGF-<font face="Symbol">b </font>RECEPTOR AND MEDICINAL USES THEREOF |
WO2019114793A1 (en) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | Egfr antibody, preparation method therefor and application thereof |
CN108250297B (en) * | 2018-01-23 | 2021-07-23 | 上海生物制品研究所有限责任公司 | anti-EGFR antibodies, methods of making and uses thereof |
CN110467676B (en) * | 2019-09-24 | 2020-06-05 | 武汉奥科博泰生物科技有限公司 | Monoclonal antibody specifically binding to EGFR and anti-cancer application thereof |
-
2021
- 2021-04-26 JP JP2022565668A patent/JP2023523981A/en active Pending
- 2021-04-26 EP EP21796635.7A patent/EP4144764A4/en active Pending
- 2021-04-26 BR BR112022021785A patent/BR112022021785A2/en unknown
- 2021-04-26 WO PCT/CN2021/089782 patent/WO2021218883A1/en unknown
- 2021-04-26 AU AU2021264846A patent/AU2021264846A1/en active Pending
- 2021-04-26 MX MX2022013455A patent/MX2022013455A/en unknown
- 2021-04-26 US US17/922,327 patent/US20230257469A1/en active Pending
- 2021-04-26 KR KR1020227041598A patent/KR20230003114A/en active Search and Examination
- 2021-04-26 CA CA3176671A patent/CA3176671A1/en active Pending
- 2021-04-26 CN CN202180023395.5A patent/CN115335411A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4144764A4 (en) | 2024-07-17 |
JP2023523981A (en) | 2023-06-08 |
US20230257469A1 (en) | 2023-08-17 |
BR112022021785A2 (en) | 2022-12-06 |
WO2021218883A1 (en) | 2021-11-04 |
KR20230003114A (en) | 2023-01-05 |
CA3176671A1 (en) | 2021-11-04 |
AU2021264846A1 (en) | 2022-12-08 |
CN115335411A (en) | 2022-11-11 |
EP4144764A1 (en) | 2023-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20191463A1 (en) | BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3 | |
MX2022009306A (en) | Cd28 single domain antibodies and multivalent and multispecific constructs thereof. | |
EA201990781A1 (en) | ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION | |
PE20190514A1 (en) | BISPECIFIC ANTIBODY TYPE UNION PROTEINS THAT SPECIFICALLY JOIN CD3 AND CD123 | |
PE20220142A1 (en) | HEAVY CHAIN ANTIBODIES THAT BIND TO PSMA | |
FI3683235T3 (en) | Anti-il-33 antibodies and uses thereof | |
AR077088A1 (en) | BISPECIFIC PROTEINS OF ANTIGEN UNION | |
WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
MX2022000652A (en) | Claudin18 antibodies and methods of treating cancer. | |
RU2018104703A (en) | TUMOR-SPECIFIC ANTIBODY AGAINST EGFR AND ITS APPLICATION | |
MX2020002921A (en) | Claudin6 antibodies and methods of treating cancer. | |
MX2021011330A (en) | Claudin-6 antibodies and drug conjugates. | |
MX2022002855A (en) | Anti-oncolytic virus antigen antibodies and methods of using same. | |
MX2022010665A (en) | Antibodies binding il4r and uses thereof. | |
BR112022021397A2 (en) | ANTI-CD73 ANTIBODY, ISOLATED POLYPEPTIDE, NUCLEIC ACID MOLECULE, VECTOR, HOST CELL, CONJUGATE, FUSION PROTEIN OR MULTIESPECIFIC ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION, USE OF ANTIBODY AND HYBRIDOMA CELL LINE | |
PE20220763A1 (en) | MATERIALS AND METHODS FOR MODULATING T-CELL-MEDIATED IMMUNITY | |
MY196874A (en) | Humanized anti-basigin antibodies and the use thereof | |
FI3797121T3 (en) | Antibodies specific for cd3 and uses thereof | |
PE20231080A1 (en) | ANTIBODIES THAT BIND CD3 AND CD19 | |
PE20221256A1 (en) | ANTIBODIES DIRECTED TO FLT3 AND USE THEREOF | |
RU2016148682A (en) | ANTIBODIES AGAINST RECEPTOR-3 TO EPIDERMAL GROWTH HUMAN FACTOR (HER3) RELATING TO HER3 BETAIL PIN | |
PE20230389A1 (en) | PROTEINS THAT COMPRISE BINDING DOMAINS TO THE CD3 ANTIGEN AND USES OF THESE | |
PE20191743A1 (en) | BI-SPECIFIC ANTIBODIES ANTI-PD-L1-ANTI-TIM3 | |
PE20240086A1 (en) | ANTI-CD122 ANTIBODIES AND USES OF THESE | |
RU2016135418A (en) | NEW ANALYSIS FOR HUMAN PERIODINE DETECTION |